Obermatt
See Similar Stocks →

Mineralys Therapeutics

NSQ:MLYS · US6031701013
BiotechnologySmall

360

21
Medium confidence — indicative
Profit price79
Owner Earnings Yield1
Dividend Yield1
Price/Sales13
Price/Book38
Return on Capital56
Cash Return on Capital73
Return on Equity67
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth28
Long-Term EPS Growth8
Reinvestment94
Price momentum49
Debt load66
Refinancing79
Debt Payback1
Liquidity16
Analyst ratings63
Opinion Changes50
Price Target Upside70
Market mood81
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mineralys Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2019
Employees84
Websitemineralystx.com
ISINUS6031701013
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesNephrologyEndocrinologyInternal DiseasesCardiovascularBiopharmaBiotechnologyMedicalPharmaceutical

Description

Mineralys Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to target diseases driven by dysregulated aldosterone. The company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective…

Analysis

Middle-of-the-road

Mineralys Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
51
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
13
—
—
—
Price/Earnings
73
—
—
—
Price/Book
38
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
18
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mineralys Therapeutics with its peers
Lexeo Therapeutics
NMQ:LXEO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Actuate Therapeutics
NMQ:ACTU
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kalvista Pharmaceuticals
NMQ:KALV
60
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ardelyx
NMQ:ARDX
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →